litlas
ログインアカウント作成

Jacob Schachter

1994–2025 年に発表

94
論文数
28,795
被引用数
61
h 指数
88
i10 指数

被引用数

Jacob Schachter の年別被引用数1993 年: 被引用 1 件1995 年: 被引用 1 件1996 年: 被引用 1 件1997 年: 被引用 2 件1998 年: 被引用 3 件2000 年: 被引用 3 件2001 年: 被引用 4 件2002 年: 被引用 5 件2003 年: 被引用 6 件2004 年: 被引用 6 件2005 年: 被引用 15 件2006 年: 被引用 12 件2007 年: 被引用 11 件2008 年: 被引用 18 件2009 年: 被引用 13 件2010 年: 被引用 20 件2011 年: 被引用 25 件2012 年: 被引用 44 件2013 年: 被引用 64 件2014 年: 被引用 74 件2015 年: 被引用 245 件2016 年: 被引用 466 件2017 年: 被引用 501 件2018 年: 被引用 519 件2019 年: 被引用 1,457 件2020 年: 被引用 1,587 件2021 年: 被引用 1,732 件2022 年: 被引用 1,487 件2023 年: 被引用 1,068 件2024 年: 被引用 1,591 件2025 年: 被引用 784 件2026 年: 被引用 23 件1994 年は被引用が無いため表示していません1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,632 件、この内訳の 24.3%中国: 引用元論文 1,802 件、この内訳の 12.1%ドイツ: 引用元論文 878 件、この内訳の 5.9%イタリア: 引用元論文 874 件、この内訳の 5.9%フランス: 引用元論文 783 件、この内訳の 5.2%イギリス: 引用元論文 743 件、この内訳の 5%オーストラリア: 引用元論文 668 件、この内訳の 4.5%オランダ: 引用元論文 548 件、この内訳の 3.7%カナダ: 引用元論文 475 件、この内訳の 3.2%スペイン: 引用元論文 451 件、この内訳の 3%スイス: 引用元論文 444 件、この内訳の 3%日本: 引用元論文 330 件、この内訳の 2.2%
0%24.3%その他 22%

機関

分野

  • Medicine64.1%
  • Biochemistry, Genetics and Molecular Biology24.6%
  • Immunology and Microbiology7.2%
  • Engineering0.9%
  • Nursing0.7%
  • Computer Science0.4%
  • その他2.1%

トピック

  • Cancer Immunotherapy and Biomarkers16%
  • CAR-T cell therapy research8.1%
  • Immunotherapy and Immune Responses7.5%
  • Melanoma and MAPK Pathways6%
  • Cutaneous Melanoma Detection and Management4.6%
  • Immune Cell Function and Interaction3%
  • その他54.8%

共著者

全論文

検索で開く
  1. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

    著者: Erez N. Baruch, Ilan Youngster, Guy Ben‐Betzalel, Rona Ortenberg, Adi Lahat, Lior H. Katz, Katerina Adler, Daniela Dick‐Necula, Stephen Raskin, Naamah Bloch, Д. Л. Ротин, Liat Anafi, Camila Avivi, Jenny Melnichenko, Yael Steinberg‐Silman, Ronac Mamtani, Hagit Harati, Nethanel Asher, Ronnie Shapira‐Frommer, Tal Brosh‐Nissimov, Yael Eshet, Shira Ben-Simon, Ziv Oren, Md Abdul Wadud Khan, Moran Amit, Nadim J. Ajami, Iris Barshack, Jacob Schachter, Jennifer A. Wargo, Omry Koren, Gal Markel, Ben Boursi - Science 2020 被引用: 1,682

  2. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    著者: Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas - New England Journal of Medicine 2015 被引用: 5,847

  3. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

    著者: Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, Bogusława Karaszewska, Axel Hauschild, E. Levchenko, Vanna Chiarion‐Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Helen Gogas, Mario Mandalà, John B.A.G. Haanen, Célèste Lebbé, Andrzej Maćkiewicz, Piotr Rutkowski, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith T. Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Maurizio Voi, Dirk Schadendorf, Georgina V. Long - New England Journal of Medicine 2019 被引用: 1,376

  4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    著者: Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long - The Lancet Oncology 2019 被引用: 1,153

  5. Identification of bacteria-derived HLA-bound peptides in melanoma

    著者: Shelly Kalaora, Adi Nagler, Deborah Nejman, Michal Alon, Chaya Barbolin, Eilon Barnea, Steven L. C. Ketelaars, Kuoyuan Cheng, Kévin Vervier, Noam Shental, Yuval Bussi, Ron Rotkopf, Ronen Levy, Gil Benedek, Sophie Trabish, Tali Dadosh, Smadar Levin‐Zaidman, Leore T. Geller, Kun Wang, Polina Greenberg, Gal Yagel, Aviyah Peri, Garold Fuks, Neerupma Bhardwaj, Alexandre Reuben, Leandro C. Hermida, Sarah B. Johnson, Jessica Galloway-Peña, William C. Shropshire, Chantale Bernatchez, Cara Haymaker, Reetakshi Arora, Lior Roitman, Raya Eilam, Adina Weinberger, Maya Lotan‐Pompan, Michal Lotem, Arie Admon, Yishai Levin, Trevor D. Lawley, David J. Adams, Mitchell P. Levesque, Michal J. Besser, Jacob Schachter, Ofra Golani, Eran Segal, Naama Geva‐Zatorsky, Eytan Ruppin, Pia Kvistborg, Scott N. Peterson, Jennifer A. Wargo, Ravid Straussman, Yardena Samuels - Nature 2021 被引用: 437

  6. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    著者: Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, D. Stroiakovski, M. Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V. Long, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D. Rubin, Shonda M Little, Dirk Schadendorf - New England Journal of Medicine 2014 被引用: 2,655

  7. Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

    著者: Steven O’Day, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Richard Kefford, Jean‐Jacques Grob, Laurent Mortier, Caroline Robert, Jacob Schachter, Alessandro Testori, Jacek Mackiewicz, Philip Friedlander, Claus Garbe, Selma Ugurel, Frances A. Collichio, Wei Guo, Joelle Lufkin, Safi R. Bahcall, Vojo Vukovic, Axel Hauschild - Journal of Clinical Oncology 2013 被引用: 386

  8. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

    著者: Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M. Kirkwood - New England Journal of Medicine 2017 被引用: 1,475

  9. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    著者: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert - The Lancet 2017 被引用: 1,239

  10. Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

    著者: Michal Harel, Rona Ortenberg, Siva Karthik Varanasi, Kailash Chandra Mangalhara, Mariya Mardamshina, Ettai Markovits, Erez N. Baruch, Victoria Tripple, May Arama-Chayoth, Eyal Greenberg, Anjana Shenoy, Rüveyda Ayasun, Naama Knafo, Shihao Xu, Liat Anafi, Gali Arad, Georgina D. Barnabas, Shira Ashkenazi, Michal J. Besser, Jacob Schachter, Marcus Bosenberg, Gerald S. Shadel, Iris Barshack, Susan M. Kaech, Gal Markel, Tamar Geiger - Cell 2019 被引用: 340

  11. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    著者: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci ほか 32 名 - The Lancet Oncology 2021 被引用: 389

  12. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    著者: Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Carmen Loquai, Thomas Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira‐Frommer, René González, John M. Kirkwood, Jedd D. Wolchok, Alexander M.M. Eggermont, Xiaoyun Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, Sunyu Kang, Adil Daud - The Lancet Oncology 2015 被引用: 1,564

  13. Early and late hematologic toxicity following CD19 CAR-T cells

    著者: Shalev Fried, Abraham Avigdor, Bella Bielorai, Amilia Meir, Michal J. Besser, Jacob Schachter, Avichai Shimoni, Arnon Nagler, Amos Toren, Elad Jacoby - Bone Marrow Transplantation 2019 被引用: 401

  14. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

    著者: Meir Rozenbaum, Amilia Meir, Yarden Aharony, Orit Itzhaki, Jacob Schachter, Ilan Bank, Elad Jacoby, Michal J. Besser - Frontiers in Immunology 2020 被引用: 215

  15. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    著者: Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M. Kirkwood, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Eduard Gasal, Monique Tan, Georgina V. Long, Dirk Schadendorf - New England Journal of Medicine 2020 被引用: 407

  16. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

    著者: Jean‐Jacques Grob, René González, Nicole Basset‐Séguin, Olga Vornicova, Jacob Schachter, Abhishek Joshi, Nicolás Meyer, Florent Grange, Josep M. Piulats, Jessica R. Bauman, Pingye Zhang, Burak Gümüşçü, Ramona F. Swaby, Brett Hughes - Journal of Clinical Oncology 2020 被引用: 289

  17. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

    著者: Caroline Robert, Matteo S. Carlino, Catriona M. McNeil, Antoni Ribas, Jean‐Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M. Petrella, Arnold Blaustein, Michal Lotem, Ana Arance, Adil Daud, Omid Hamid, James Larkin, James R. Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V. Long - Journal of Clinical Oncology 2023 被引用: 113

  18. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

    著者: Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolás Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz‐Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean‐Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz‐Merino, André van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Öcek Baş, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina V. Long - Journal of Clinical Oncology 2022 被引用: 162

  19. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

    著者: Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasal, Razi Ghori, Scott J. Diede, Elizabeth Croydon, Antoni Ribas, Paolo A. Ascierto - Journal for ImmunoTherapy of Cancer 2020 被引用: 173

  20. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    著者: Georgina V. Long, Axel Hauschild, Mario Santinami, John M. Kirkwood, Victoria Atkinson, Mario Mandalà, Barbara Merelli, Vanna Chiarion‐Sileni, Marta Nyakas, Andrew Haydon, Caroline Dutriaux, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, James Larkin, Monique Tan, Sachin Bajirao Adnaik, Paul Burgess, Tarveen Jandoo, Reinhard Dummer - New England Journal of Medicine 2024 被引用: 125

  21. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

    著者: Paolo A. Ascierto, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Светлана Проценко, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Natalia V. Zhukova, Jacob Schachter, Yibing Yan, Ivor Caro, Christian Hertig, Cloris Xue, Lieke Kusters, Grant A. McArthur, Ralf Gutzmer - The Lancet Oncology 2022 被引用: 104

  22. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    著者: Brett Hughes, E. Munoz-Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, B. Gumuscu, Ramona F. Swaby, Jean‐Jacques Grob - Annals of Oncology 2021 被引用: 200

  23. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

    著者: Michal J. Besser, Ronnie Shapira‐Frommer, Orit Itzhaki, Avraham J. Treves, Douglas Zippel, Daphna Levy, Adva Kubi, Noa Shoshani, Dragoslav Zikich, Yaara Ohayon, Daniel Ohayon, Bruria Shalmon, Gal Markel, Ronit Yerushalmi, Sara Apter, Alon Ben‐Nun, Eytan Ben‐Ami, Avichai Shimoni, Arnon Nagler, Jacob Schachter - Clinical Cancer Research 2013 被引用: 383

  24. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

    著者: Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey, Roxana Dronca, Richard W. Joseph, C. Boutros, Le Min, Georgina V. Long, Jacob Schachter, Igor Puzanov, Reinhard Dummer, Jianxin Lin, Nageatte Ibrahim, Scott J. Diede, Matteo S. Carlino, Anthony M. Joshua - European Journal of Cancer 2020 被引用: 100